Novel cyanocombretastatins as potent tubulin polymerisation inhibitors.

Bioorganic & medicinal chemistry letters 20121101

Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes.

Pharmaceutical research 20121001

The vascular targeting agent Combretastatin-A4 directly induces autophagy in adenocarcinoma-derived colon cancer cells.

Biochemical pharmacology 20120901

Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.

Molecular nutrition & food research 20120901

Fluorescence lifetime imaging of E-combretastatin uptake and distribution in live mammalian cells.

European journal of cancer (Oxford, England : 1990) 20120801

In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4.

European journal of medicinal chemistry 20120801

Colon tumor growth and antivascular treatment in mice: complementary assessment with MR elastography and diffusion-weighted MR imaging.

Radiology 20120801

Synthesis and structure-activity relationships of benzophenone-bearing diketopiperazine-type anti-microtubule agents.

Bioorganic & medicinal chemistry 20120715

Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks.

Journal of medicinal chemistry 20120712

High-sensitivity in vivo imaging for tumors using a spectral up-conversion nanoparticle NaYF4: Yb3+, Er3+ in cooperation with a microtubulin inhibitor.

Nanoscale 20120707

Synthesis and biological evaluation of 1-benzylidene-3,4-dihydronaphthalen-2-one as a new class of microtubule-targeting agents.

Journal of medicinal chemistry 20120628

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20120615

Discovery and optimization of a series of 2-aryl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazoles as novel anticancer agents.

Journal of medicinal chemistry 20120614

Conformationnally restricted naphthalene derivatives type isocombretastatin A-4 and isoerianin analogues: synthesis, cytotoxicity and antitubulin activity.

European journal of medicinal chemistry 20120601

Synthesis of chalcone-amidobenzothiazole conjugates as antimitotic and apoptotic inducing agents.

Bioorganic & medicinal chemistry 20120601

Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.

Die Pharmazie 20120601

Design, synthesis and biological evaluation of novel chalcone derivatives as antitubulin agents.

Bioorganic & medicinal chemistry 20120515

Synthesis, biological evaluation, and molecular docking studies of 2,6-dinitro-4-(trifluoromethyl)phenoxysalicylaldoxime derivatives as novel antitubulin agents.

Bioorganic & medicinal chemistry 20120515

Cholesterol superlattice modulates CA4P release from liposomes and CA4P cytotoxicity on mammary cancer cells.

Biophysical journal 20120502

Discovery of small molecule inhibitors that interact with γ-tubulin.

Chemical biology & drug design 20120501

Antineoplastic agents. 548. Synthesis of iodo- and diiodocombstatin phosphate prodrugs.

Journal of natural products 20120323

Dehydrative fragmentation of 5-hydroxyalkyl-1H-tetrazoles: a mild route to alkylidenecarbenes.

Organic letters 20120316

Substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones and analogues: synthesis, cytotoxic activity, and study of the mechanism of action.

Journal of medicinal chemistry 20120308

Synthesis and biological evaluation of 1,4-diaryl-2-azetidinones as specific anticancer agents: activation of adenosine monophosphate activated protein kinase and induction of apoptosis.

Journal of medicinal chemistry 20120308

Diffusion-weighted MR imaging allows monitoring the effect of combretastatin A4 phosphate on rabbit implanted VX2 tumor model: 12-day dynamic results.

European journal of radiology 20120301

Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A-1.

Bioorganic & medicinal chemistry 20120301

Synthesis and structure-activity relationship study of antimicrotubule agents phenylahistin derivatives with a didehydropiperazine-2,5-dione structure.

Journal of medicinal chemistry 20120209

Synthesis, biological evaluation, and molecular docking studies of cinnamic acyl 1,3,4-thiadiazole amide derivatives as novel antitubulin agents.

Bioorganic & medicinal chemistry 20120201

Design, synthesis, biological evaluation and molecular modeling of 1,3,4-oxadiazoline analogs of combretastatin-A4 as novel antitubulin agents.

Bioorganic & medicinal chemistry 20120115

Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity.

Journal of medicinal chemistry 20120112

Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature.

Nanomedicine : nanotechnology, biology, and medicine 20120101

Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck.

Annals of oncology : official journal of the European Society for Medical Oncology 20120101

Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.

Anti-cancer drugs 20120101

c-Jun N-terminal kinase mediates microtubule-depolymerizing agent-induced microtubule depolymerization and G2/M arrest in MCF-7 breast cancer cells.

Anti-cancer drugs 20120101

Synthesis, biological evaluation and molecular modeling of 1,2,3-triazole analogs of combretastatin A-1.

Bioorganic & medicinal chemistry 20120101

Vascular disrupting agent drug classes differ in effects on the cytoskeleton.

PloS one 20120101

[Liposome formulations of combretastatin A4 and 4-arylcoumarin analog prodrugs: antitumor effect in the mouse model of breast cancer].

Biomeditsinskaia khimiia 20120101

Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability.

Journal of medicinal chemistry 20111222

5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2. The impact of bridging groups at position C-2.

Journal of medicinal chemistry 20111222

Patterning cells and shear flow conditions: convenient observation of endothelial cell remoulding, enhanced production of angiogenesis factors and drug response.

Lab on a chip 20111221

Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft.

Cancer letters 20111215

One-pot synthesis and biological evaluation of 2-pyrrolidinyl-4-amino-5-(3',4',5'-trimethoxybenzoyl)thiazole: a unique, highly active antimicrotubule agent.

European journal of medicinal chemistry 20111201

Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships.

European journal of medicinal chemistry 20111101

1,1-Diarylalkenes as anticancer agents: dual inhibitors of tubulin polymerization and phosphodiesterase 4.

Bioorganic & medicinal chemistry 20111101

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.

International journal of cancer 20111015

The metabolic fate of isocombretastatin A-4 in human liver microsomes: identification, synthesis and biological evaluation of metabolites.

ChemMedChem 20111004

Design, synthesis, and cytotoxicity of novel 3-arylidenones derived from alicyclic ketones.

Chemical biology & drug design 20111001

Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties.

Journal of medicinal chemistry 20110908

Synthesis and biological activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents.

Journal of medicinal chemistry 20110908

Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4.

ChemMedChem 20110905

Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents.

Medical engineering & physics 20110901

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology 20110901

Design, synthesis and antiproliferative activities of biarylolefins based on polyhydroxylated and carbohydrate scaffolds.

European journal of medicinal chemistry 20110901

Synthesis and biological evaluation of 1-(4'-Indolyl and 6'-Quinolinyl) indoles as a new class of potent anticancer agents.

European journal of medicinal chemistry 20110901

Synthesis, biochemical and molecular modelling studies of antiproliferative azetidinones causing microtubule disruption and mitotic catastrophe.

European journal of medicinal chemistry 20110901

Investigation of protein induction in tumour vascular targeted strategies by MALDI MSI.

Methods (San Diego, Calif.) 20110801

Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.

Bioorganic & medicinal chemistry 20110801

Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents.

Journal of medicinal chemistry 20110728

Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues.

Journal of medicinal chemistry 20110728

Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.

Journal of natural products 20110722

Design, synthesis, biological evaluation, and structure-activity relationships of substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonates as new tubulin inhibitors mimicking combretastatin A-4.

Journal of medicinal chemistry 20110714

A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing.

European journal of medicinal chemistry 20110701

A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.

British journal of clinical pharmacology 20110601

In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.

International journal of radiation oncology, biology, physics 20110601

Imidazolone-amide bridges and their effects on tubulin polymerization in cis-locked vinylogous combretastatin-A4 analogues: synthesis and biological evaluation.

Bioorganic & medicinal chemistry 20110601

Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.

Journal of medicinal chemistry 20110512

TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice.

The Journal of clinical investigation 20110502

Synthesis of novel antimitotic agents based on 2-amino-3-aroyl-5-(hetero)arylethynyl thiophene derivatives.

Bioorganic & medicinal chemistry letters 20110501

4,5-Diaryl-3-aminopyrazole derivatives as analogs of Combretastatin A-4: synthesis and biological evaluation.

Archiv der Pharmazie 20110501

BubR1 is required for the mitotic block induced by combretastatin-A4 and a novel cis-restricted ß-lactam analogue in human cancer cells.

International journal of molecular medicine 20110501

Synthesis, biological evaluation, and molecular docking studies of resveratrol derivatives possessing chalcone moiety as potential antitubulin agents.

Bioorganic & medicinal chemistry 20110415

Design, synthesis, and biological evaluation of novel γ-carboline ketones as anticancer agents.

European journal of medicinal chemistry 20110401

Design and synthesis of novel enhanced water soluble hydroxyethyl analogs of combretastatin A-4.

Bioorganic & medicinal chemistry letters 20110401

Acetyl analogs of combretastatin A-4: synthesis and biological studies.

Bioorganic & medicinal chemistry 20110401

Synthesis and cytotoxic evaluation of N-(4-methoxy-1H-benzo[d]imidazol-7-yl)-arylsulfonamide and N-aryl-(4-methoxy-1H-benzo[d]imidazol)-7-sulfonamide analogs of combretastatin A-4.

Journal of Asian natural products research 20110401

Application of plant allylpolyalkoxybenzenes in synthesis of antimitotic phenstatin analogues.

Bioorganic & medicinal chemistry letters 20110315

Antitumor agents. 284. New desmosdumotin B analogues with bicyclic B-ring as cytotoxic and antitubulin agents.

Journal of medicinal chemistry 20110310

Enhanced anti-tumor activity by the combination of TRAIL/Apo-2L and combretastatin A-4 against human colon cancer cells via induction of apoptosis in vitro and in vivo.

Cancer letters 20110301

Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system.

Journal of controlled release : official journal of the Controlled Release Society 20110210

Synthesis and biological evaluation of 3,5-diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as anticancer agents.

European journal of medicinal chemistry 20110201

Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.

Microvascular research 20110101

Combretastatin-induced hypertension and the consequences for its combination with other therapies.

Vascular pharmacology 20110101

Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues.

European journal of medicinal chemistry 20110101

Developments of combretastatin A-4 derivatives as anticancer agents.

Current medicinal chemistry 20110101

Synthesis of antiproliferative flavones from calycopterin, major flavonoid of Calycopteris floribunda Lamk.

Bioorganic & medicinal chemistry 20110101

Stable combretastatin A-4 analogues with sub-nanomolar efficacy against chemoresistant HT-29 cells.

International journal of clinical pharmacology and therapeutics 20110101

Computational modeling of tumor response to vascular-targeting therapies--part I: validation.

Computational and mathematical methods in medicine 20110101

Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.

Current medicinal chemistry 20110101

Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells.

Oncology research 20110101

Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.

International journal of nanomedicine 20110101

Synthesis and evaluation of azetidinone analogues of combretastatin A-4 as tubulin targeting agents.

Journal of medicinal chemistry 20101223

Lead identification of conformationally restricted β-lactam type combretastatin analogues: synthesis, antiproliferative activity and tubulin targeting effects.

European journal of medicinal chemistry 20101201

Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-aryl/arylaminobenzo[b]thiophene derivatives as a novel class of antiproliferative agents.

European journal of medicinal chemistry 20101201

Synthesis, molecular modeling and biological evaluation of guanidine derivatives as novel antitubulin agents.

Bioorganic & medicinal chemistry 20101201

Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.

Molecular cancer therapeutics 20101201

Synthesis of antimitotic polyalkoxyphenyl derivatives of combretastatin using plant allylpolyalkoxybenzenes.

Journal of natural products 20101129

Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance.

Journal of medicinal chemistry 20101125

Self-assembled core-shell vascular-targeted nanocapsules for temporal antivasculature and anticancer activities.

Small (Weinheim an der Bergstrasse, Germany) 20101122

Effects of a combretastatin A4 analogous chalcone and its Pt-complex on cancer cells: A comparative study of uptake, cell cycle and damage to cellular compartments.

Biochemical pharmacology 20101115

The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.

The Journal of pharmacology and experimental therapeutics 20101101

Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents.

Journal of medicinal chemistry 20101028

Non-invasive imaging of combretastatin activity in two tumor models: Association with invasive estimates.

Acta oncologica (Stockholm, Sweden) 20101001

4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model.

Journal of medicinal chemistry 20100923

1,2,3-triazole analogs of combretastatin A-4 as potential microtubule-binding agents.

Bioorganic & medicinal chemistry 20100915

Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors.

Journal of medicinal chemistry 20100909

Structure-activity relationships of indole compounds derived from combretastatin A4: synthesis and biological screening of 5-phenylpyrrolo[3,4-a]carbazole-1,3-diones as potential antivascular agents.

European journal of medicinal chemistry 20100901

Design, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents.

European journal of medicinal chemistry 20100901

Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro.

Pharmaceutical research 20100901

A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities.

Biomaterials 20100901

Regioselective hydrostannation of diarylalkynes directed by a labile ortho bromine atom: an easy access to stereodefined triarylolefins, hybrids of combretastatin A-4 and isocombretastatin A-4.

European journal of medicinal chemistry 20100901

Synthesis and in vitro antitumor activity of new 4,5-dihydropyrazole derivatives.

Bioorganic & medicinal chemistry 20100901

[Progress in the study of tubulin inhibitors].

Yao xue xue bao = Acta pharmaceutica Sinica 20100901

Synthesis and anti-cancer activity of chalcone linked imidazolones.

Bioorganic & medicinal chemistry letters 20100815

Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents.

Investigational new drugs 20100801

Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells.

Investigational new drugs 20100801

Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.

British journal of pharmacology 20100801

Combretastatin A4 phosphate: a novel vascular disrupting agent.

Future oncology (London, England) 20100801

Antitumor agents 273. Design and synthesis of N-alkyl-thiocolchicinoids as potential antitumor agents.

Bioorganic & medicinal chemistry letters 20100715

Substituted 2-(3',4',5'-trimethoxybenzoyl)-benzo[b]thiophene derivatives as potent tubulin polymerization inhibitors.

Bioorganic & medicinal chemistry 20100715

Identification of the human UDP-glucuronosyltransferases involved in the glucuronidation of combretastatin A-4.

Drug metabolism and disposition: the biological fate of chemicals 20100701

Structural determinants of resveratrol for cell proliferation inhibition potency: experimental and docking studies of new analogs.

European journal of medicinal chemistry 20100701

Regio- and stereospecific synthesis of mono-beta-d-glucuronic acid derivatives of combretastatin A-1.

Journal of natural products 20100625

Synthesis, molecular modeling and biological evaluation of dithiocarbamates as novel antitubulin agents.

Bioorganic & medicinal chemistry 20100615

Binding conformations and QSAR of CA-4 analogs as tubulin inhibitors.

Journal of enzyme inhibition and medicinal chemistry 20100601

[New strategies for NSCLC: is inhibition of tumour vasculature useful].

Pneumologie (Stuttgart, Germany) 20100601

Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues.

Journal of medicinal chemistry 20100527

Highly chemo- and stereoselective palladium-catalyzed transfer semihydrogenation of internal alkynes affording cis-alkenes.

The Journal of organic chemistry 20100507

Synthesis and biological evaluation of combretastatin analogs as cell cycle inhibitors of the G1 to S transition in Saccharomyces cerevisiae.

Bioorganic & medicinal chemistry letters 20100501

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

British journal of cancer 20100427

Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate.

Journal of medicinal chemistry 20100408

Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents.

ChemMedChem 20100406

Lead identification of conformationally restricted benzoxepin type combretastatin analogs: synthesis, antiproliferative activity, and tubulin effects.

Journal of enzyme inhibition and medicinal chemistry 20100401

Pyrazolone-fused combretastatins and their precursors: synthesis, cytotoxicity, antitubulin activity and molecular modeling studies.

Bioorganic & medicinal chemistry 20100401

An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins.

Journal of natural products 20100326

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100301

Oxazole-bridged combretastatin A analogues with improved anticancer properties.

ChemMedChem 20100301

Exploring the effect of 2,3,4-trimethoxy-phenyl moiety as a component of indolephenstatins.

European journal of medicinal chemistry 20100201

A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent.

Bioorganic & medicinal chemistry 20100115

Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4.

Journal of medicinal chemistry 20100114

Novel hybrids from lamellarin D and combretastatin A 4 as cytotoxic agents.

European journal of medicinal chemistry 20100101

Synthesis and antitumor-evaluation of cyclopropyl-containing combretastatin analogs.

Bioorganic & medicinal chemistry letters 20091215

Vascular disrupting activity of tubulin-binding 1,5-diaryl-1H-imidazoles.

Journal of medicinal chemistry 20091210

Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091115

Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity.

Bioorganic & medicinal chemistry 20091115

Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.

Bioorganic & medicinal chemistry 20091115

Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

European radiology 20091101

Synthesis, biological evaluation of 1,1-diarylethylenes as a novel class of antimitotic agents.

ChemMedChem 20091101

Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

Bioorganic & medicinal chemistry 20091001

Design, synthesis and structure-activity relationship of 2-(3',4',5'-trimethoxybenzoyl)-benzo[b]furan derivatives as a novel class of inhibitors of tubulin polymerization.

Bioorganic & medicinal chemistry 20091001

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

Cancer research 20091001

AVE8062: a new combretastatin derivative vascular disrupting agent.

Expert opinion on investigational drugs 20091001

E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes.

Bioorganic & medicinal chemistry 20090915

2-Arylamino-4-amino-5-aroylthiazoles. 'One-pot' synthesis and biological evaluation of a new class of inhibitors of tubulin polymerization.

Journal of medicinal chemistry 20090910

Isocombretastatins A: 1,1-diarylethenes as potent inhibitors of tubulin polymerization and cytotoxic compounds.

Bioorganic & medicinal chemistry 20090901

Antineoplastic agents. 579. Synthesis and cancer cell growth evaluation of E-stilstatin 3: a resveratrol structural modification.

Journal of natural products 20090901

Design and synthesis of 2-(3-benzo[b]thienyl)-6,7-methylenedioxyquinolin-4-one analogues as potent antitumor agents that inhibit tubulin assembly.

Journal of medicinal chemistry 20090813

Isocombretastatins a versus combretastatins a: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent.

Journal of medicinal chemistry 20090723

1,4-Diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase.

The Journal of pharmacology and experimental therapeutics 20090701

Anticancer strategies involving the vasculature.

Nature reviews. Clinical oncology 20090701

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090701

A diaryl sulfide, sulfoxide, and sulfone bearing structural similarities to combretastatin A-4.

European journal of medicinal chemistry 20090601

Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20090601

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.

Clinical cancer research : an official journal of the American Association for Cancer Research 20090601

Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.

The oncologist 20090601

Antineoplastic agents. 578. Synthesis of stilstatins 1 and 2 and their water-soluble prodrugs.

Journal of natural products 20090327

Antineoplastic agents. 565. Synthesis of combretastatin D-2 phosphate and dihydro-combretastatin D-2.

Journal of natural products 20090325

Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.

European journal of cancer (Oxford, England : 1990) 20090301

Synthesis and biological evaluation of cis-locked vinylogous combretastatin-A4 analogues: derivatives with a cyclopropyl-vinyl or a cyclopropyl-amide bridge.

Bioorganic & medicinal chemistry letters 20090301

Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions.

Journal of magnetic resonance imaging : JMRI 20090301

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.

Thyroid : official journal of the American Thyroid Association 20090301

Up-regulation of connective tissue growth factor in endothelial cells by the microtubule-destabilizing agent combretastatin A-4.

Molecular cancer research : MCR 20090201

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Expert opinion on investigational drugs 20090201

In vitro and in vivo phase II metabolism of combretastatin A-4: evidence for the formation of a sulphate conjugate metabolite.

Xenobiotica; the fate of foreign compounds in biological systems 20090201

Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression.

Journal of medicinal chemistry 20090122

Design, synthesis and biological evaluation of novel stilbene-based antitumor agents.

Bioorganic & medicinal chemistry 20090115

Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.

Investigative radiology 20090101

Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affects growth of B16-F10 tumors.

Acta biochimica Polonica 20090101

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats.

Vascular pharmacology 20090101

Synthesis and structure-activity relationships of 2-amino-1-aroylnaphthalene and 2-hydroxy-1-aroylnaphthalenes as potent antitubulin agents.

Journal of medicinal chemistry 20081225

Novel A-ring and B-ring modified combretastatin A-4 (CA-4) analogues endowed with interesting cytotoxic activity.

Journal of medicinal chemistry 20081009

Vibrational spectra and ab initio molecular orbital calculations of the novel anti-cancer drug combretastatin A-4 prodrug.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20081001

Naphthylphenstatins as tubulin ligands: synthesis and biological evaluation.

Bioorganic & medicinal chemistry 20081001

Synthesis and biological evaluation of polymethoxylated 4-heteroarylcoumarins as tubulin assembly inhibitor.

Bioorganic & medicinal chemistry 20081001

Tumour vascular disrupting agents: combating treatment resistance.

The British journal of radiology 20081001

Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.

Bioorganic & medicinal chemistry letters 20080915

Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-N,N-dimethylamino benzo[b]furan derivatives as inhibitors of tubulin polymerization.

Bioorganic & medicinal chemistry 20080915

1,2,3,4-tetrahydro-2-thioxopyrimidine analogs of combretastatin-A4.

European journal of medicinal chemistry 20080901

Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy.

Bioorganic & medicinal chemistry 20080901

Antineoplastic agents. 552. Oxidation of combretastatin A-1: trapping the o-quinone intermediate considered the metabolic product of the corresponding phosphate prodrug.

Journal of natural products 20080901

Asymmetric synthesis of 2,3-dihydro-2-arylquinazolin-4-ones: methodology and application to a potent fluorescent tubulin inhibitor with anticancer activity.

Journal of medicinal chemistry 20080814

Synthesis and biological evaluation of new disubstituted analogues of 6-methoxy-3-(3',4',5'-trimethoxybenzoyl)-1H-indole (BPR0L075), as potential antivascular agents.

Bioorganic & medicinal chemistry 20080801

Discovery of 4-amino and 4-hydroxy-1-aroylindoles as potent tubulin polymerization inhibitors.

Journal of medicinal chemistry 20080724

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.

British journal of cancer 20080722

Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20080701

Synthesis and antitumor activity of benzils related to combretastatin A-4.

Bioorganic & medicinal chemistry letters 20080601

Diarylmethyloxime and hydrazone derivatives with 5-indolyl moieties as potent inhibitors of tubulin polymerization.

Bioorganic & medicinal chemistry 20080601

Design, synthesis, and biological evaluation of thiophene analogues of chalcones.

Bioorganic & medicinal chemistry 20080515

2-(6-aryl-3(Z)-hexen-1,5-diynyl)anilines as a new class of potent antitubulin agents.

Journal of medicinal chemistry 20080508

Synthesis and biological activity of fluorinated combretastatin analogues.

Journal of medicinal chemistry 20080508

The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460.

Apoptosis : an international journal on programmed cell death 20080501

1,5-Disubstituted 1,2,3-triazoles as cis-restricted analogues of combretastatin A-4: Synthesis, molecular modeling and evaluation as cytotoxic agents and inhibitors of tubulin.

Bioorganic & medicinal chemistry 20080501

Tubulysin analogs incorporating desmethyl and dimethyl tubuphenylalanine derivatives.

Bioorganic & medicinal chemistry letters 20080501

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.

International journal of cancer 20080415

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

Cancer research 20080401

Combretastatin A-4 activates AMP-activated protein kinase and improves glucose metabolism in db/db mice.

Pharmacological research 20080401

Synthesis and biological evaluation of 1-methyl-2-(3',4',5'-trimethoxybenzoyl)-3-aminoindoles as a new class of antimitotic agents and tubulin inhibitors.

Journal of medicinal chemistry 20080313

Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients.

International journal of radiation oncology, biology, physics 20080301

Efficacy of selected natural products as therapeutic agents against cancer.

Journal of natural products 20080301

Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.

Journal of natural products 20080301

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death.

Blood 20080215

Design, synthesis, and in vitro antitumor activity of new 1,4-diarylimidazole-2-ones and their 2-thione analogues.

Bioorganic & medicinal chemistry letters 20080201

Segmentation of dynamic contrast enhanced magnetic resonance imaging data.

Acta oncologica (Stockholm, Sweden) 20080101

Solution-phase parallel synthesis and biological evaluation of combretatriazoles.

Journal of combinatorial chemistry 20080101

The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.

Acta oncologica (Stockholm, Sweden) 20080101

3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.

Bioorganic & medicinal chemistry letters 20071215

In vitro metabolism study of combretastatin A-4 in rat and human liver microsomes.

Drug metabolism and disposition: the biological fate of chemicals 20071201

Mechanism of retinoblastoma tumor cell death after focal chemotherapy, radiation, and vascular targeting therapy in a mouse model.

Investigative ophthalmology & visual science 20071201

Combretastatin a-4 analogs as anticancer agents.

Mini reviews in medicinal chemistry 20071201

Conformationally restricted macrocyclic analogues of combretastatins.

Bioorganic & medicinal chemistry letters 20071115

Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.

International journal of radiation oncology, biology, physics 20071115

Replacement of the lactone moiety on podophyllotoxin and steganacin analogues with a 1,5-disubstituted 1,2,3-triazole via ruthenium-catalyzed click chemistry.

Bioorganic & medicinal chemistry 20071101

Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4.

Bioorganic & medicinal chemistry letters 20071101

Tumour targeting by microtubule-depolymerizing vascular disrupting agents.

Expert opinion on therapeutic targets 20071101

Combretastatin A4-induced differential cytotoxicity and reduced metastatic ability by inhibition of AKT function in human gastric cancer cells.

The Journal of pharmacology and experimental therapeutics 20071001

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model.

The Journal of clinical endocrinology and metabolism 20070801

Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.

Bioorganic & medicinal chemistry letters 20070701

Synthesis and biological activity of naphthalene analogues of phenstatins: naphthylphenstatins.

Bioorganic & medicinal chemistry letters 20070615

Arylthioindole inhibitors of tubulin polymerization. 3. Biological evaluation, structure-activity relationships and molecular modeling studies.

Journal of medicinal chemistry 20070614

Synthesis and biological evaluation of 2- and 3-aminobenzo[b]thiophene derivatives as antimitotic agents and inhibitors of tubulin polymerization.

Journal of medicinal chemistry 20070503

The concise synthesis of chalcone, indanone and indenone analogues of combretastatin A4.

Bioorganic & medicinal chemistry 20070501

Characterizing the tumor response to treatment with combretastatin A4 phosphate.

International journal of radiation oncology, biology, physics 20070501

A Ramberg-Bäcklund route to the stilbenoid anti-cancer agents combretastatin A-4 and DMU-212.

Chemical communications (Cambridge, England) 20070428

Vascular disrupting agents in clinical development.

British journal of cancer 20070423

Synthesis and evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anticancer agents.

Journal of medicinal chemistry 20070419

Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.

International journal of radiation oncology, biology, physics 20070401

N-Phenyl-N'-(2-chloroethyl)urea analogues of combretastatin A-4: Is the N-phenyl-N'-(2-chloroethyl)urea pharmacophore mimicking the trimethoxy phenyl moiety?

Bioorganic & medicinal chemistry letters 20070401

Evaluation of the vascular targeting agent combretastatin a-4 prodrug on retinal neovascularization in the galactose-fed dog.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070401

Potent antitubulin tumor cell cytotoxins based on 3-aroyl indazoles.

Journal of medicinal chemistry 20070308

Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.

Bioorganic & medicinal chemistry letters 20070301

Highly potent triazole-based tubulin polymerization inhibitors.

Journal of medicinal chemistry 20070222

Synthesis and cytotoxic activities of 4,5-diarylisoxazoles.

Bioorganic & medicinal chemistry letters 20070215

Synthesis and activity of Combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents.

Bioorganic & medicinal chemistry letters 20070215

MZ3 induces apoptosis in human leukemia cells.

Cancer chemotherapy and pharmacology 20070201

Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure.

Neoplasia (New York, N.Y.) 20070201

Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells.

Apoptosis : an international journal on programmed cell death 20070101

Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model.

Cancer imaging : the official publication of the International Cancer Imaging Society 20070101

Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularization.

The Journal of clinical investigation 20061201

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.

Molecular cancer therapeutics 20061101

Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.

Journal of medicinal chemistry 20061019

2-amino and 2'-aminocombretastatin derivatives as potent antimitotic agents.

Journal of medicinal chemistry 20061019

Synthesis and biological evaluation of 2-(3',4',5'-trimethoxybenzoyl)-3-amino 5-aryl thiophenes as a new class of tubulin inhibitors.

Journal of medicinal chemistry 20061019

Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.

Bioorganic & medicinal chemistry 20061001

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.

Science (New York, N.Y.) 20060922

Synthesis and cytotoxic evaluation of combretafurans, potential scaffolds for dual-action antitumoral agents.

Journal of medicinal chemistry 20060824

Interaction of 4-arylcoumarin analogues of combretastatins with microtubule network of HBL100 cells and binding to tubulin.

Biochemistry 20060801

Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060801

4,5-Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: synthesis and evaluation as anti-mitotic and cytotoxic agents.

Bioorganic & medicinal chemistry 20060701

Synthesis and biological evaluation of (3,4,5-trimethoxyphenyl)indol-3-ylmethane derivatives as potential antivascular agents.

Bioorganic & medicinal chemistry 20060701

Promising new treatments for neovascular age-related macular degeneration.

Expert opinion on investigational drugs 20060701

Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060701

Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.

Neoplasia (New York, N.Y.) 20060701

Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents.

Journal of medicinal chemistry 20060629

Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation.

Bioorganic & medicinal chemistry 20060615

Medicinal chemistry of combretastatin A4: present and future directions.

Journal of medicinal chemistry 20060601

Novel combretastatin analogues endowed with antitumor activity.

Journal of medicinal chemistry 20060601

Current development status of small-molecule vascular disrupting agents.

Current opinion in investigational drugs (London, England : 2000) 20060601

A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.

AAPS PharmSciTech 20060407

Benzoylphenylurea sulfur analogues with potent antitumor activity.

Journal of medicinal chemistry 20060406

Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines.

Bioorganic & medicinal chemistry letters 20060301

C8c-C15 monoseco-analogues of the phenanthroquinolizidine alkaloids julandine and cryptopleurine exhibiting potent anti-angiogenic properties.

Bioorganic & medicinal chemistry letters 20060101

NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.

Anti-cancer drugs 20060101

In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation.

Anticancer research 20060101

The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.

Acta oncologica (Stockholm, Sweden) 20060101

Macular degeneration: the latest in current medical management.

Retina (Philadelphia, Pa.) 20060101

Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.

PDA journal of pharmaceutical science and technology 20060101

Anti-vascular agent Combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression.

BMC cancer 20060101

Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.

Bioorganic & medicinal chemistry letters 20051215

Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors.

Bioorganic & medicinal chemistry letters 20051201

Plant-based anticancer molecules: a chemical and biological profile of some important leads.

Bioorganic & medicinal chemistry 20051101

Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.

Radiology 20051101

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.

The Journal of clinical investigation 20051101

Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).

Chemotherapy 20051001

Antineoplastic agents. 509: synthesis of fluorcombstatin phosphate and related 3-halostilbenes(1).

Journal of natural products 20051001

A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach.

Journal of medicinal chemistry 20050922

Synthesis and preliminary biological evaluation of new anti-tubulin agents containing different benzoheterocycles.

Bioorganic & medicinal chemistry letters 20050915

Taking down tumors: vascular disrupting agents entering clinical trials.

Journal of the National Cancer Institute 20050907

Structure-based discovery of a boronic acid bioisostere of combretastatin A-4.

Chemistry & biology 20050901

Stilbenophane analogues of deoxycombretastatin A-4.

The Journal of organic chemistry 20050805

Synthesis and biological activity of mustard derivatives of combretastatins.

Bioorganic & medicinal chemistry letters 20050801

Antineoplastic agents. 515. Synthesis of human cancer cell growth inhibitors derived from 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene.

Journal of natural products 20050801

Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration.

Neoplasia (New York, N.Y.) 20050801

Synthesis and biological evaluation of vinylogous combretastatin A-4 derivatives.

Organic & biomolecular chemistry 20050721

Tumor physiologic response to combretastatin A4 phosphate assessed by MRI.

International journal of radiation oncology, biology, physics 20050701

Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment.

Cancer research 20050701

Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41.

Journal of medicinal chemistry 20050616

New antitubulin derivatives in the combretastatin A4 series: synthesis and biological evaluation.

Bioorganic & medicinal chemistry 20050601

Synthesis and cytotoxic evaluation of combretafurazans.

Journal of medicinal chemistry 20050505

Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.

Current oncology reports 20050301

Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice.

European journal of cancer (Oxford, England : 1990) 20050301

Antimitotic activity and reversal of breast cancer resistance protein-mediated drug resistance by stilbenoids from Bletilla striata.

Bioorganic & medicinal chemistry letters 20050215

Phase I trial of combretastatin a-4 phosphate with carboplatin.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050215

Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines.

Journal of medicinal chemistry 20050210

Quantitative structure-activity relationship (5D-QSAR) study of combretastatin-like analogues as inhibitors of tubulin assembly.

Journal of medicinal chemistry 20050127

Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety.

Journal of medicinal chemistry 20050127

Combretastatin A-4 prodrug in the treatment of a murine model of retinoblastoma.

Investigative ophthalmology & visual science 20050101

Evaluation of anti-vascular therapy with texture analysis.

Anticancer research 20050101

Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression.

Anticancer research 20050101

Arylthioindoles, potent inhibitors of tubulin polymerization.

Journal of medicinal chemistry 20041202

The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death.

The American journal of pathology 20041001

Combretastatin A4 phosphate: background and current clinical status.

Expert opinion on investigational drugs 20040901

Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040901

Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents.

Journal of medicinal chemistry 20040812

A new family of quinoline and quinoxaline analogues of combretastatins.

Bioorganic & medicinal chemistry letters 20040716

Vascular-targeting therapies for treatment of malignant disease.

Cancer 20040615

Synthesis and structure-activity relationships of 3-aminobenzophenones as antimitotic agents.

Journal of medicinal chemistry 20040520

Examination of the 1,4-disubstituted azetidinone ring system as a template for combretastatin A-4 conformationally restricted analogue design.

Bioorganic & medicinal chemistry letters 20040503

Combretastatin A4 phosphate.

Anti-cancer drugs 20040301

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040215

Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).

British journal of cancer 20040126

Vascular targeting agents as cancer therapeutics.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040115

Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.

European journal of cancer (Oxford, England : 1990) 20040101

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040101

Abilities of 3,4-diarylfuran-2-one analogs of combretastatin A-4 to inhibit both proliferation of tumor cell lines and growth of relevant tumors in nude mice.

Anticancer research 20040101

Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins.

Journal of medicinal chemistry 20031204

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031201

Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy.

IDrugs : the investigational drugs journal 20031101

Combretastatin A-4 analogues as antimitotic antitumor agents.

Current medicinal chemistry 20030901

Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.

Cancer science 20030901

Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030801

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030801

Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization.

Investigative ophthalmology & visual science 20030801

Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.

Journal of medicinal chemistry 20030717

(E)-1-(2-Hydroxy-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene.

Acta crystallographica. Section C, Crystal structure communications 20030701

Vascular targeting effect of combretastatin A-4 phosphate dominates the inherent angiogenesis inhibitory activity.

International journal of cancer 20030520

Novel 6,7-diphenyl-2,3,8,8a-tetrahydro-1H-indolizin-5-one analogues as cytotoxic agents.

Bioorganic & medicinal chemistry letters 20030519

Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4.

Bioorganic & medicinal chemistry letters 20030505

Synthesis, anticancer activity, and inhibition of tubulin polymerization by conformationally restricted analogues of lavendustin A.

Journal of medicinal chemistry 20030424

Antineoplastic agents. 487. Synthesis and biological evaluation of the antineoplastic agent 3,4-methylenedioxy-5,4'-dimethoxy-3'-amino-Z-stilbene and derived amino acid amides.

Journal of medicinal chemistry 20030213

Structure-activity and crystallographic analysis of benzophenone derivatives-the potential anticancer agents.

Bioorganic & medicinal chemistry letters 20030106

Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin.

Cell biochemistry and biophysics 20030101

Vascular targeting: a potential additional anti-cancer treatment.

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20030101

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

Anticancer research 20030101

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.

Anticancer research 20030101

Drug based approaches for targeting tumor vasculature: development of combretastatin A4 phosphate.

Pathophysiology of haemostasis and thrombosis 20030101

The development of combretastatin A4 phosphate as a vascular targeting agent.

International journal of radiation oncology, biology, physics 20021201

Combination of vascular targeting agents with thermal or radiation therapy.

International journal of radiation oncology, biology, physics 20021201

Enhancement of vascular targeting by inhibitors of nitric oxide synthase.

International journal of radiation oncology, biology, physics 20021201

Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors.

Thyroid : official journal of the American Thyroid Association 20021201

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.

International journal of cancer 20021101

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.

International journal of oncology 20021001

Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020801

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

Cancer research 20020615

Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate.

Journal of medicinal chemistry 20020606

Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents.

Journal of medicinal chemistry 20020606

One-pot synthesis of benzo[b]furan and indole inhibitors of tubulin polymerization.

Journal of medicinal chemistry 20020606

Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.

International journal of cancer 20020501

Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.

Neoplasia (New York, N.Y.) 20020501

The influence of combretastatin A-4 and vinblastine on interstitial fluid pressure in BT4An rat gliomas.

Cancer letters 20020425

Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation.

Journal of medicinal chemistry 20020411

Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.

NMR in biomedicine 20020401

Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.

The American journal of pathology 20020301

Synthesis and biological evaluation of 2-indolyloxazolines as a new class of tubulin polymerization inhibitors. Discovery of A-289099 as an orally active antitumor agent.

Bioorganic & medicinal chemistry letters 20020211

The biology of the combretastatins as tumour vascular targeting agents.

International journal of experimental pathology 20020201

Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.

Acta oncologica (Stockholm, Sweden) 20020101

Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcoma.

Acta oncologica (Stockholm, Sweden) 20020101

Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate.

Anticancer research 20020101

Critical assessment of angiogenesis inhibitors in clinical trials.

I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.] 20020101

Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20011201

Novel syntheses of cis and trans isomers of combretastatin A-4.

The Journal of organic chemistry 20011130

Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy.

International journal of radiation oncology, biology, physics 20011115

Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents.

Journal of medicinal chemistry 20011108

Potent anti-metastatic activity of combretastatin-A4.

International journal of oncology 20011001

The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.

Cancer research 20010915

The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4.

Bioorganic & medicinal chemistry letters 20010903

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

Cancer research 20010901

Combretastatin A-4 and hyperthermia;a potent combination for the treatment of solid tumors.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20010801

Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 20010801

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

Cancer research 20010615

Combretastatin A-4 prodrug inhibits growth of human non-small cell lung cancer in a murine xenotransplant model.

The Annals of thoracic surgery 20010501

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents.

Bioorganic & medicinal chemistry letters 20010409

Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010401

Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.

Cancer gene therapy 20010401

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue.

British journal of cancer 20010301

Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas.

FEMS immunology and medical microbiology 20010201

In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment.

International journal of radiation oncology, biology, physics 20010201

Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.

International journal of radiation biology 20010201

Design, synthesis, and biological evaluation of a series of lavendustin A analogues that inhibit EGFR and Syk tyrosine kinases, as well as tubulin polymerization.

Journal of medicinal chemistry 20010201

Targeting tumour vasculature: the development of combretastatin A4.

The Lancet. Oncology 20010201

Antimitotic and cell growth inhibitory properties of combretastatin A-4-like ethers.

Bioorganic & medicinal chemistry letters 20010108

Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma.

Oncology reports 20010101

Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.

Medical science monitor : international medical journal of experimental and clinical research 20010101

Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.

Anti-cancer drugs 20010101

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

Anticancer research 20010101

6-Alkylamino- and 2,3-dihydro-3'-methoxy-2-phenyl-4-quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.

Journal of medicinal chemistry 20001116

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

Experientia 19890215

Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study.

Molecular pharmacology 19880801